📣 VC round data is live. Check it out!
- Public Comps
- Century Therapeutics
Century Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Century Therapeutics and similar public comparables like Invivyd, Recbio, CytoDyn, TaiMed Biologics and more.
Century Therapeutics Overview
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Founded
2018
HQ

Employees
150
Website
Financials (LTM)
EV
$339M
Valuation Multiples
Start free trialCentury Therapeutics Financials
Century Therapeutics reported last 12-month revenue of $72M.
In the same LTM period, Century Therapeutics generated $72M in gross profit and had net loss of ($40M).
Revenue (LTM)
Century Therapeutics P&L
In the most recent fiscal year, Century Therapeutics reported revenue of $109M and EBITDA of $3M.
Century Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of 2% and net margin of (9%).
Financial data powered by Morningstar, Inc.
Century Therapeutics Stock Performance
Century Therapeutics has current market cap of $413M, and enterprise value of $339M.
Market Cap Evolution
Century Therapeutics' stock price is $2.29.
Century Therapeutics share price increased by 331.7% in the last year.
Century Therapeutics has an EPS (earnings per share) of $-0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $339M | $413M | -0.9% | 0.0% | 102.9% | 331.7% | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCentury Therapeutics Valuation Multiples
Century Therapeutics trades at 4.7x EV/Revenue multiple, and 130.8x EV/EBITDA.
EV / Revenue (LTM)
Century Therapeutics Financial Valuation Multiples
As of May 5, 2026, Century Therapeutics has market cap of $413M and EV of $339M.
Century Therapeutics has a P/E ratio of (10.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Century Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Century Therapeutics Margins & Growth Rates
In the most recent fiscal year, Century Therapeutics reported EBITDA margin of 2% and net margin of (9%).
Century Therapeutics Margins
Century Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Century Therapeutics Operational KPIs
Century Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Century Therapeutics Competitors
Century Therapeutics competitors include Invivyd, Recbio, CytoDyn, TaiMed Biologics, Benitec Biopharma, Ever Supreme Bio Technology, Autolus Therapeutics, Nika Pharmaceuticals, Neumora Therapeutics and Akebia Therapeutics.
Most Century Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.6x | 3.0x | (3.6x) | (2.8x) | |||
| 245.0x | 247.2x | (6.5x) | — | |||
| — | — | 49.8x | — | |||
| 19.4x | 18.9x | (3435.1x) | — | |||
| — | — | (5.6x) | — | |||
| 12.2x | 12.0x | 22.7x | — | |||
| 2.5x | 2.0x | (0.8x) | (0.8x) | |||
| — | — | (5512.1x) | — | |||
This data is available for Pro users. Sign up to see all Century Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Century Therapeutics Funding History
Before going public, Century Therapeutics raised $410M in total equity funding, across 2 rounds.
Century Therapeutics Funding Rounds
Century Therapeutics M&A Activity
Century Therapeutics has acquired 2 companies to date.
Last acquisition by Century Therapeutics was on April 11th 2024. Century Therapeutics acquired Clade Therapeutics for $35M (EV/Revenue multiple of ).
Latest Acquisitions by Century Therapeutics
| Description | Clade Therapeutics is a Cambridge, Massachusetts-headquartered biopharmaceutical company founded in 2020 that engineers off-the-shelf stem cell therapies targeting autoimmune diseases and oncology. Its proprietary platform induces regulatory T cells and modifies hematopoietic stem cells for conditions like multiple sclerosis and lupus. Backed by ARCH Venture Partners and Takeda, Clade advances preclinical candidates toward IND filings at facilities in Kendall Square. | Empirica Therapeutics is a San Diego-based developer of adoptive cell therapies targeting glioblastoma and brain metastases. The company engineers allogeneic NK cells expressing chimeric receptors against solid tumor antigens like EGFRvIII. Empirica advances its lead candidate EMP-201 through Phase 1 trials in collaboration with academic centers. |
| HQ Country | ||
| HQ City | — | — |
| Deal Date | 11 Apr 2024 | 23 Jun 2020 |
| Valuation | $35M | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Century Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Century Therapeutics
| When was Century Therapeutics founded? | Century Therapeutics was founded in 2018. |
| Where is Century Therapeutics headquartered? | Century Therapeutics is headquartered in United States. |
| How many employees does Century Therapeutics have? | As of today, Century Therapeutics has over 150 employees. |
| Who is the CEO of Century Therapeutics? | Century Therapeutics' CEO is Brent Pfeiffenberger. |
| Is Century Therapeutics publicly listed? | Yes, Century Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Century Therapeutics? | Century Therapeutics trades under IPSC ticker. |
| When did Century Therapeutics go public? | Century Therapeutics went public in 2021. |
| Who are competitors of Century Therapeutics? | Century Therapeutics main competitors include Invivyd, Recbio, CytoDyn, TaiMed Biologics, Benitec Biopharma, Ever Supreme Bio Technology, Autolus Therapeutics, Nika Pharmaceuticals, Neumora Therapeutics, Akebia Therapeutics. |
| What is the current market cap of Century Therapeutics? | Century Therapeutics' current market cap is $413M. |
| What is the current revenue of Century Therapeutics? | Century Therapeutics' last 12 months revenue is $72M. |
| What is the current revenue growth of Century Therapeutics? | Century Therapeutics revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Century Therapeutics? | Current revenue multiple of Century Therapeutics is 4.7x. |
| Is Century Therapeutics profitable? | No, Century Therapeutics is not profitable. |
| What is the current net income of Century Therapeutics? | Century Therapeutics' last 12 months net income is ($40M). |
| How many companies Century Therapeutics has acquired to date? | As of May 2026, Century Therapeutics has acquired 2 companies. |
| What was the largest acquisition by Century Therapeutics? | $35M acquisition of Clade Therapeutics on 11th April 2024 was the largest M&A Century Therapeutics has done to date. |
| What companies Century Therapeutics acquired? | Century Therapeutics acquired Clade Therapeutics and Empirica Therapeutics. |
| In how many companies Century Therapeutics has invested to date? | Century Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Century Therapeutics
Lists including Century Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

